{"subject": "CHEBI:28748", "predicate": "biolink:affects", "object": "UniProtKB:P18887", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:28258155", "PMID:29929045", "PMID:34783124"], "tmkp_confidence_score": 0.9983171550000001, "sentences": "The significant increase in CDKN1A and XRCC1 suggest a cell cycle arrest and implies an alternative NHEJ pathway in response to doxorubicin-induced DNA breaks.|NA|However, FANCD2, BRCA1 and XRCC1 foci, prominently associated with 53BP1 foci and hence DSBs resolved by cNHEJ, were only detected in doxorubicin-treated XRCC4-deficient cells.|NA", "tmkp_ids": ["tmkp:0792c702bebbc0eea6d08d4c1b4911679ae23b03775b11345d868db6cf670fe4", "tmkp:551578d2b184d7e406e3b2f81a800c880fe80a93283abbbe55e8573c2228687a", "tmkp:5fd679cb1d20061fa8cbc5fab5f65c1581afd2e6436cef845ca4f2a7f95e353f", "tmkp:ae3877b6ed48c7afbc0991e8578f84513dd12cacb2bb6a485df182d33d4d4e7f", "tmkp:bb27255bd16ceeab7135e5b967f5a9b28fd98024c4152a494c6c341dec11bf01"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "CHEBI:28748", "original_object": "UniProtKB:P18887"}
{"subject": "UMLS:C3896731", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0018874", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5767051", "PMC:7789799", "PMC:8470441", "PMC:8537004", "PMC:8582601", "PMC:8649641", "PMC:8749975", "PMC:9146966"], "tmkp_confidence_score": 0.9062430810801192, "sentences": "In a phase I/II clinical study (NCT02152956), patients with primary induction failure (PIF) or early relapsed (ER) AML received flotetuzumab monotherapy.|NA|Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia|NA|Flotetuzumab, another DART that binds CD3 and CD123, is currently being studied in a phase I clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) and intermediate/high-risk myelodysplastic syndrome (MDS) (NCT02152956).|NA|CRS was observed in all AML patients treated with Flotetuzumab and 58% of AML patients treated with Vibecotamab (XmAb14045), another CD3xCD123 BiAb.|NA|Anti-CD123 targeted immunotherapies (e.g., IMGN-632, flotetuzumab) have shown promising activity in preclinical models of acute myeloid leukemia (AML) and are under current clinical investigation in early-phase trials for patients with relapsed/refractory AML.|NA", "tmkp_ids": ["tmkp:0ddc6b4ff3aa20320a8f482c7838cfe264703c133ec628f485c56b939a5db29f", "tmkp:0e5a620b980c332b613fc8ceaf2ed7e857f16ff6eedae9bcfd6a8162c66f37b1", "tmkp:4d63d3a050e2bfb5d9772f7e5f4d1c6e380e28831e399b0f6be1e39acac522ba", "tmkp:6f137fb4cf08ce6229ca22c41f4230de8d0c7865e4d13b3ea83562ca7a84ff52", "tmkp:739248eaefe6faedc9de66c46d5bb61b2c036242be46a6d8e5dd21f9e1e11667", "tmkp:8025446698f27df311ceb61ba143f55d6fa3b910546335d467f70a407c67cbb2", "tmkp:bf5b8934ba854e1c6c329caa7359b4c5e2613a195c140b3f2b0d571d95d61d8e", "tmkp:fe6bc6720edd353932f568c8efc2e0f34ea89fef18207a061414eb573eb8d95f"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15223", "original_object": "MONDO:0018874"}
{"subject": "UNII:5L3SX16QBQ", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0004979", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8692160", "PMC:9003539", "PMC:7652256", "PMC:7050994"], "tmkp_confidence_score": 0.9007020194955808, "sentences": "Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma|NA|Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma|NA|Steroid-naive participants with mild asthma who demonstrated an early and late asthmatic response when challenged with one of four common perennial or seasonal inhaled aeroallergens (cat dander, birch pollen, house dust mite, or grass-mix) were administered intranasal GSK2245035 20 ng or placebo once weekly for 8 weeks.|NA|Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}?9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one e (GSK2245035), a highly potent and selective intranasal toll-like receptor 7 agonist for the treatment of asthma     |NA", "tmkp_ids": ["tmkp:7deb7f39b82e6e2b7f4dd23824d42b072513ebd2a559a66246f59a097b093a63", "tmkp:a8279ae370c7f77d498cef12a6b2bf788aa75af1c8a7015e90972331181d20be", "tmkp:e3654b3a2e7e3ea71a89856a770edf077fa821ff0b6003944b3968958de81967", "tmkp:c4ece597e17769922b5df7bfdb38a45ae19fca5df0e08438f2d7a09e78c426a9"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB16076", "original_object": "MONDO:0004979"}
{"subject": "UniProtKB:P05067", "predicate": "biolink:affects", "object": "UniProtKB:P42261", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7476873", "PMC:7476873"], "tmkp_confidence_score": 0.9513757249999999, "sentences": "In APP/PS1 mice injected with either GFP-GluA1-WT or GFP-GluA1-4KQ, we found a specific increase in GluA1 in both the hippocampus (Figures 5F and 5G) and, to a lesser extent, in the cortex (Figures S1A and S1B) compared with APP/PS1 controls.|NA|In APP/PS1 mice injected with either GFP-GluA1-WT or GFP-GluA1-4KQ, we found a specific increase in GluA1 in both the hippocampus (Figures 5F and 5G) and, to a lesser extent, in the cortex (Figures S1A and S1B) compared with APP/PS1 controls.|NA", "tmkp_ids": ["tmkp:3688bb3077ec93168ad862780642febd79ee1c71d6cec82b29da296559e47d24", "tmkp:41a205e3eb1ede0878ee0c2112145fdaae890c7b8bbb3628e81e0602cbbbf8ba"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P05067", "original_object": "UniProtKB:P42261"}
{"subject": "CHEBI:30812", "predicate": "biolink:contributes_to", "object": "MONDO:0005559", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7747873"], "tmkp_confidence_score": 1.240363873664695, "sentences": "Furthermore, in the model of cortical injection of ferrous chloride, neurodegeneration is limited to the cortex.|NA", "tmkp_ids": ["tmkp:152341005c16f9080cde8c31134f64a87c0b2da4aca9f058704014a59e73ad5f"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13569", "original_object": "HP:0002180"}
{"subject": "CHEBI:37758", "predicate": "biolink:contributes_to", "object": "HP:0001945", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8570226"], "tmkp_confidence_score": 0.83672262923918, "sentences": "Similar to bismuth, iodoform and iodine toxicity manifests with neuropsychiatric symptoms of malaise, decreased appetite, headache, agitation, depression or delirium, drowsiness and semi-coma, gastrointestinal symptoms of nausea and vomiting, and constitutional symptoms such as fever and tachycardia.|NA", "tmkp_ids": ["tmkp:03efebc69131dcf90a6398b8b13813d82338a6ecca67fe07a4e5b544815913e1"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13813", "original_object": "HP:0001945"}
{"subject": "DRUGBANK:DB13961", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0011382", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:156645", "PMC:7510211", "PMC:7510211", "PMC:156645"], "tmkp_confidence_score": 0.7994774097501699, "sentences": "In the second study, Tomer and coworkers also demonstrated changes in platelet and red cell activation markers in subjects with SCD following fish oil supplementation for one year, resulting in fewer pain episodes compared to subjects supplemented with n-6 fatty acids.|NA|A large trial in Sudan showed school absences were significantly decreased in children with sickle cell anemia taking fish oil compared to those taking placebo.|NA|A trial in Georgia showed significantly decreased pain and decreased platelet activation in adults with sickle cell anemia on large daily quantities of fish oil capsules compared to adults on large daily quantities of olive oil capsules as placebo control.|NA|In two separate supplementation studies involving SCD subjects, changes in the fatty acid composition of red cell phospholipids were obtained after supplementation with fish oil containing high amounts of long-chain polyunsaturated n-3 fatty acids.|NA", "tmkp_ids": ["tmkp:07a5b28914805f12ef0602131994006bcd113051c6714078c1dbaea005709466", "tmkp:80a804c3392a5af37a7713a149526d0145a20fadd6cdd44c983906b88f40c42d", "tmkp:cb95e2154dee69bc4fd0b8ad57cea58834e7127cd95722a516c7cf80e7401f9b", "tmkp:5f674a418ae96cb84f2111f094180d881524f50d4cbaf7d053cf70c6e16ac555"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13961", "original_object": "MONDO:0011382"}
{"subject": "CHEBI:9332", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0000010", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6556801", "PMC:7430156", "PMC:4887100", "PMC:6903708", "PMC:7779487"], "tmkp_confidence_score": 0.999518288, "sentences": "Additionally, chloramphenicol and trimethoprim/sulfamethoxazole are also common choices for treatment of UTI and diarrhea associated with E. coli in humans and animals.|NA|Sulfamethoxazole (SMZ or SMX), another FDA-approved ligand, is an antibiotic used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis.|NA|UPEC within IBCs are protected from both phagocytosis by PMNs and many antibiotics, particularly the first-line drug trimethoprim-sulfamethoxazole, which has increased efficacy against UTI because it concentrates in the urine but is relatively cell-impermeant.|NA|Urinary tract infections (UTIs) caused by Escherichia coli have been historically managed with oral antibiotics including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole.|NA|Trimethoprim-sulfamethoxazole (TMP-SMX) was the preferred antibiotic for UTI treatment for many years due to its efficacy and low cost.|NA", "tmkp_ids": ["tmkp:81d75d641f9db1bcdadeb7c29dd014c0fc8595571b0506043d890fbdf83fef83", "tmkp:01757ae45cbffa67779682d35917ed235e14f0356045c2ae081dde8911dca4a0", "tmkp:9e70772947ff13767f0a77d73eca87d07dea2d6bea4960b04a2e81ea6a8075f1", "tmkp:af9b01ace3280a44624fe65adf859027c34eb9827ada4fb0ff16cc22ddde36a5", "tmkp:723c9f4ff52d3c789641cd4ab734eb9786a072d33332b83f7e2031c8176a1a07"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB01015", "original_object": "HP:0000010"}
{"subject": "CHEBI:6890", "predicate": "biolink:affects", "object": "UniProtKB:Q02156", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5865770"], "tmkp_confidence_score": 0.99955505, "sentences": "Finally, the EPO + MPSS group exhibited the highest protein expression levels for AQP4 following reperfusion, and PKC inhibition partially but significantly inhibited this AQP4 upregulation (P<0.05;|NA", "tmkp_ids": ["tmkp:af9009dcefe29cbbe3eb6fb2e20da3baf717efcec8517fe84cb8cba683c6ad8c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "CHEBI:6890", "original_object": "UniProtKB:Q02156"}
{"subject": "CHEBI:5186", "predicate": "biolink:affects", "object": "UniProtKB:Q9UNQ0", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:32712543", "PMC:9229252"], "tmkp_confidence_score": 0.9996719199999999, "sentences": "The combination of the FUC and DOX decreased ABCC1, ABCG2, and ABCB1 expression.|NA|Besides, the treatment also reduces the expressions of transporter genes ABCC1, ABCG2 and ABCB1 when compared to Fx or DOX monotreatment.|NA", "tmkp_ids": ["tmkp:99a7ed4379d0ffec0fb70f2bc88564b694ac9e08f41fac825a77cdbe6bdc1d55", "tmkp:33eadf5eb3a8ccbcc40ce00f5117935f23442f8cafc83dadb48294e0f13b6781"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB15462", "original_object": "UniProtKB:Q9UNQ0"}
{"subject": "CHEBI:17833", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0010726", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3785941", "PMC:3785941", "PMC:3055984", "PMC:7922555", "PMC:3113846"], "tmkp_confidence_score": 0.8085291529305163, "sentences": "Furthermore, the authors rescued the RTT-specific phenotypes by expressing wild type MECP2 or by treating mutant RTT neurons with IGF1 and gentamicin, showing the proof-of-principle in developing an in vitro platform for screening potential chemical therapies RTT.|NA|Furthermore, the authors rescued the RTT-specific phenotypes by expressing wild type MECP2 or by treating mutant RTT neurons with IGF1 and gentamicin, showing the proof-of-principle in developing an in vitro platform for screening potential chemical therapies RTT.|NA|In this study, we provide the first comparative evaluation of novel aminoglycosides NB30, NB54, NB84, and gentamicin in a number of clinically relevant RTT models.|NA|Furthermore, gentamicin treatment on RTT iPSCs-derived neurons enhanced MECP2 protein levels and increased glutamatergic synapse, further confirming that patient-specific iPSCs can correct neuronal phenotypes.|NA|We performed comparative study of suppression effects of the novel NB54 and gentamicin on three MECP2 nonsense mutations (R294X, R270X and R168X) common in RTT, using ex vivo treatment of primary fibroblasts from RTT patients harboring these mutations and testing for the C-terminal containing full-length MeCP2.|NA", "tmkp_ids": ["tmkp:dfb71ab260bb400efe780760fd8b74e1e2ab2b7cb6023b72522923bf21428e4e", "tmkp:21e68ed547d51e146df033e2be396415d74c1ad3e186e82b4d2bdb81f77753b0", "tmkp:b458eea146bf46e5428e3640ca15d80e010b4e696d77903ed52046a6feeedf08", "tmkp:0690f8b5ae19cc1ec7611bc4bcf130fc6af630837e622da51f3b72a997c8fefb", "tmkp:fec6872feeecb497101adacc4b7693e7a0f397d274fbee9d34711a73f0e9229e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00798", "original_object": "MONDO:0010726"}
{"subject": "CHEBI:59695", "predicate": "biolink:contributes_to", "object": "MONDO:0000437", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4418056"], "tmkp_confidence_score": 0.99930584, "sentences": "However, the clinical uses of cyproheptadine hydrochloride is limited by its side effects such as somnolence, excitation, hallucinations, ataxia, tachycardia, muscle twitching, occasionally gastric pain, dry mucous surfaces, mydriasis, and rubeosis of the face (Von M?hlendahl and Krienke, 1978).|NA", "tmkp_ids": ["tmkp:8f2a89141c8ca9225029c228d841cc271552f0a2bf001c0f95d71e07b92de000"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:59695", "original_object": "HP:0001251"}
{"subject": "UMLS:C0010592", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0030953", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8328932", "PMC:8785578", "PMC:7025671"], "tmkp_confidence_score": 0.9994875, "sentences": "Since chronic conjunctival hyperemia is considered a sign of immune dysregulation leading to a cycle of persistent inflammation, certain immunomodulatory and anti-inflammatory therapies in the form of corticosteroids, NSAIDs, and cyclosporine may be prescribed as well.|NA|In addition, 0.05?0.1% cyclosporine eye drops have also been reported to relieve symptoms and signs such as tearing, discharge, size of the papilla, conjunctival hyperemia, and corneal neovascularization in VKC.|NA|Subconjunctival CsA was safe and effective in treating ocular allergy through improving conjunctival hyperemia and reducing eosinophilic cell count with no significant ocular side effects.|NA", "tmkp_ids": ["tmkp:d2b579a7894a97fd1dc3eb1b913c2cf8acab79415e02e2e04730854a98a23db6", "tmkp:9cfd3804e61138d13f0e6e96189b6375b04cad62c7959237ecd61bd00bdee828", "tmkp:06d6f8ccce2cd108051dbea9c67a083630c6d2c54ebb4ad4233c297806ed3ad5"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00091", "original_object": "HP:0030953"}
{"subject": "UMLS:C0010592", "predicate": "biolink:contributes_to", "object": "HP:0030953", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5870249", "PMC:7709448"], "tmkp_confidence_score": 0.999033005, "sentences": "On the other hand, topical cyclosporine in cats has been related with certainly grade of intolerance and adverse effects like irritation, chemosis, conjunctival hyperemia and blepharitis.|NA|Additionally there are barriers to patient tolerance and acceptance of cyclosporine A therapy including burning, ocular stinging and conjunctival hyperemia.|NA", "tmkp_ids": ["tmkp:7c3e01fa9386799817f6eebd55538d8e3ea03aadd45a16ebbdd6de989bdaf7f9", "tmkp:7ab620be6820079bde91f432360520c74d919ff6798df9110a3ca9c6edf5e51b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00091", "original_object": "HP:0030953"}
{"subject": "CHEBI:50845", "predicate": "biolink:contributes_to", "object": "MONDO:0005560", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4627638"], "tmkp_confidence_score": 0.7856996915395076, "sentences": "Despite broad-spectrum coverage, including doxycycline and streptomycin for presumed brucellosis, she continued to have low-grade fever and encephalopathy and developed kidney failure.|NA", "tmkp_ids": ["tmkp:ad84a0418892e5a0f59f9b57e7c66be1d48b95a2c65bbc0e3fc989321da18cc1", "tmkp:cb77ba243bbf40aeb44ca761f9d0d636665ccb31e2cec4d6118e3eda749978c0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00254", "original_object": "HP:0001298"}
{"subject": "UMLS:C1122087", "predicate": "biolink:contributes_to", "object": "MONDO:0003664", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8293207"], "tmkp_confidence_score": 0.6950698142964401, "sentences": "We report a 38-year-old female patient affected with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) who developed mild hemolytic anemia (Hb = 10.5 vs. >12 gr/dL), indolent oral ulceration, ANA (1:1280, homogeneous pattern), and anti-dsDNA antibody positivity following 8 months of therapy with an adalimumab biosimilar (GP2017).|NA", "tmkp_ids": ["tmkp:cefaef64504687092c7a1f419035acf1c3aeae7000209a8289df1b2c96535645"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00051", "original_object": "MONDO:0003664"}
{"subject": "UNII:781E2AXH0K", "predicate": "biolink:contributes_to", "object": "HP:0003326", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9067419"], "tmkp_confidence_score": 1.3017308763792057, "sentences": "Leg cramps, myalgia, and arthralgia are reported among IV ferric gluconate side-effects, but rhabdomyolysis is not .|NA", "tmkp_ids": ["tmkp:6e458a38e13b07a1e5b2e5098c7f938350cbed120eb31f7640982be13415846e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB14488", "original_object": "HP:0003326"}
{"subject": "CHEBI:5537", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0002018", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3657930"], "tmkp_confidence_score": 1.1447375178919097, "sentences": "Nausea VAS score was lower in both tropisetron and granisetron groups in comparison to the controls at all points of time, except for the 8-h measurement for tropisetron.|NA", "tmkp_ids": ["tmkp:db8dab5caf5071af0d6ce210c592bee88c3c9fcd77b58921ac6c02242279a15b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00889", "original_object": "HP:0002018"}
{"subject": "MONDO:0008315", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:4672", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7449903", "PMC:8560597"], "tmkp_confidence_score": 0.6171503292608909, "sentences": "Although this study provides a promising concept for the treatment of prostate cancer, the efficacy of CaO2@HMSNs-PAA is not as ideal as some clinical antitumor drugs, such as docetaxel which has been widely used as one of the most potent antitumor therapy for prostate cancer with a significant clinical benefit in survival.|NA|Schematic diagram of AS1411@MPDA?DTX?mediated synergistic therapy for prostate cancer and the underlying mechanism.|NA", "tmkp_ids": ["tmkp:4e269386b61ed9bb56f4701813246a4c72ed1d34eb720203e93387c6a771eb26", "tmkp:b3eda266e1cca6b29b3ab66c9eacd304725c998f2581313f902d0411bd0fc650"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0008315", "original_object": "DRUGBANK:DB01248"}
{"subject": "UniProtKB:P00533", "predicate": "biolink:affects", "object": "DRUGBANK:DB15037", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6242943"], "tmkp_confidence_score": 0.9996675, "sentences": "Treatment of ELTN+FDTN@PEG-PLA led to decreased expression level of p-EGFR and p-STAT3 than free drugs (ELTN+FDTN), which might be attributed to the long circulation and tumor targeting effect enabled by the NPs.|NA", "tmkp_ids": ["tmkp:8ce93ca45350b0f346082a4a51bdbe4fd049daea6e8da215b09457e4b51d5cd1"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:P00533", "original_object": "DRUGBANK:DB15037"}
{"subject": "CHEBI:15358", "predicate": "biolink:contributes_to", "object": "HP:0000969", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5404986", "PMC:7691956"], "tmkp_confidence_score": 0.7929201186971693, "sentences": "Histones were also greatly increased in the circulation of patients with trauma-induced lung injury, and histone infusion in mice increased cytokine production, endothelial damage, coagulation, PMN infiltration, and edema; the mechanism involved plasma membrane binding and calcium influx.|NA|In the H&E staining, the result of which was consistent with that of the vascular permeability assay, the lungs of histone-infused mice showed congestion and edema and were concomitant with neutrophil infiltration in the alveolar capillaries, which was attenuated in the ADSCs+histones group (Fig.?1d).|NA", "tmkp_ids": ["tmkp:1ca2b717ab9514eec1c2c825843b5525e7fa4a764d926eba5b095dd03ea4b869", "tmkp:9271916754b33a0b148d1efc801b236da7ff46f0e4c2ea7741f30fb3a0a8040e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:15358", "original_object": "HP:0000969"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:affects", "object": "UniProtKB:O43678", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8766223"], "tmkp_confidence_score": 0.9994586, "sentences": "Figure 2A illustrates the time line for one participant receiving AZD1222. Figure 2B documents a transient yet statistically significant increase in CD14+CD16+ pro-inflammatory monocytes on day 2 for the AZD1222 group (p <?0.0001).|NA", "tmkp_ids": ["tmkp:20d54258ed188420493c29a8dc67048d063a8434f145bfdbf651f731c131d699"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "DRUGBANK:DB15656", "original_object": "UniProtKB:O43678"}
{"subject": "UniProtKB:P01579", "predicate": "biolink:affects", "object": "CHEBI:28544", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8020625"], "tmkp_confidence_score": 0.99916315, "sentences": "CbP/siPD-L1@Dig led to the highest secretion of IFN-? by inguinal lymph node cells in comparison to PBS and other treatment groups, indicating the presenting of antigen fragments and activation of lymphoid cells by DCs (Fig. S24b).|NA", "tmkp_ids": ["tmkp:d175bbe651f699810791abeecc05685859e36200a4c43b7bf657852f14209e1b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P01579", "original_object": "DRUGBANK:DB01396"}
{"subject": "UNII:6897GXD6OE", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0001945", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8764906"], "tmkp_confidence_score": 0.8487249357374929, "sentences": "In case of gastric intolerance, nausea or fever, intravenous iron preparations such as ferric carboxymaltose in high doses or low molecular weight dextran iron can be used.|NA", "tmkp_ids": ["tmkp:7c60206490e3204c9ca221bba17de24349203e6dbae20c1e46f3d74a73379157"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB08917", "original_object": "HP:0001945"}
{"subject": "MONDO:0004992", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:27899", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4656047", "PMC:9229203", "PMC:4924505", "PMC:4924505", "PMC:9055504"], "tmkp_confidence_score": 0.23814971698862153, "sentences": "Zn-cis@pyrolipid releases cisplatin and pyrolipid in a triggered manner and synergistically induced cancer cell apoptosis and necrosis.|NA|The results of in vivo experiments confirm that the CP/CQ@MSN?HtB/Cu2+ NPs provide effective cisplatin/Cu2+ synergistic therapy against cancer, which is consistent with other results in the literature.|NA|The UCNP@P-Pt enabled an efficient cellular uptake of cisplatin, resulting in a more efficient killing of cancer cells than pristine cisplatin or cisplatin-conjugated polymer prodrugs alone (Figure 4C).|NA|Lin et al. reported that UCNPs (?-NaYF:Yb3+, Er3+) assembled with cisplatin-conjugated polymer prodrugs (UCNP@P-Pt) can efficiently deliver cisplatin to cancer cells and allow the optical imaging of the delivery process in vivo (Figure 4A).|NA|This increase of the cytotoxic properties of the Fe3O4@SiO2@Au NPs, due to the synergic effect between the presence of cPt plus Au NPs and laser irradiation, makes these NPs perspective agents for potential (MRI)-guided stimulated chemo-photothermal treatment of cancer.|NA", "tmkp_ids": ["tmkp:4862543b5cf2b113f77632e11afa493fc39c8525693ac2e0fd82d2bea7c9abdc", "tmkp:b269cfede33dd73181bf6230dc9e69366b1d20ffa1fe46f3ee73a124b38eecf6", "tmkp:17f5433cf5820080bdfe2d2f36be11d051e8431e215e5972dc3645f3bbb726b9", "tmkp:6403676836d8b651187162ce839106b0aba834e7bd8669357380a69ed85a3b00", "tmkp:c57bee9bc68e92649094f0b93c4a084a30c5c226f01b1e6400425939b0ffc51b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00515"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0005015", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9068501", "PMC:9068501", "PMC:9068501", "PMC:9068501", "PMC:8540274"], "tmkp_confidence_score": 0.99948038, "sentences": "Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine |NA|Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine |NA|Immune response data after a single dose of the AZD1222 vaccine in patients with diabetes are limited.|NA|This clinical study evaluated immune responses after the first dose of the AZD1222 vaccine in patients with diabetes.|NA|A 41-year-old man with diabetes under well medical control who works as an emergency physician received his first dose of AZD1222 2 weeks prior to the onset of symptoms.|NA", "tmkp_ids": ["tmkp:a62a7e0f040ba57ea8459c6e840dcb02038827908c798a40d46897d8ea0f56c4", "tmkp:11941715f101c24e7491ac9698eb4159f2af2fee71bc46b1760558f30a3b9b0d", "tmkp:e6150dec5bfc2205d45ba8d0a1643ee00f698d59e0f82050b8d2d76cdbcd6538", "tmkp:8750f0ea64cd729368413a508bcb4648411b08346640d43de56729ab8a08be18", "tmkp:23141b0581c90aa95afe31ced6d58eaaf9f8936fd5f3f6e528cbfb4f3d44c413"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "MONDO:0005015"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:contributes_to", "object": "MONDO:0010528", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8904009"], "tmkp_confidence_score": 0.9426937, "sentences": "In severe AEs, the frequency of anosmia, acute kidney injury, acute liver damage, thrombocytopenic purpura, thrombocytopenia, neurological complications, and severe skin reactions was higher in AZD1222 than BNT162b2 (Figure?3, Table?5).|NA", "tmkp_ids": ["tmkp:1db964377254611343309e3fe38e0bc68af885a580c4517e041be520aa1dd51e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "MONDO:0010528"}
{"subject": "MONDO:0004992", "predicate": "biolink:contributes_to", "object": "CHEBI:15551", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7432113"], "tmkp_confidence_score": 0.2473304249124015, "sentences": "The ability of GO@T hybrids to modulate the release of PGE2 in PC-3 and HREC was investigated as marker for the activation of inflammatory processes, which can have a crucial role both in carcinogenesis and cancer progression as well as in the angiogenic switch-on mechanism.|NA", "tmkp_ids": ["tmkp:4158a9e3223823ab0cb4dd7838f2c54ff5f875dc4d48571dda7eac37d99fa173", "tmkp:8844c4cb592ffce77d779803499e8bab1cd45d8b3ae22453f19ba4bc35d3932d"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00917"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:contributes_to", "object": "HP:0030528", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8875181"], "tmkp_confidence_score": 0.99786264, "sentences": "B?hler et al. reported on a 27-year-old female with no past medical history who developed flu-like symptoms followed by a paracentral scotoma OS two days after receiving the AZD1222 vaccine.|NA", "tmkp_ids": ["tmkp:371e6734233ebbe65957155a53fb6192cec3124256295201fbc7d1fa5e2fe179"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "HP:0030528"}
{"subject": "HP:0001510", "predicate": "biolink:contributes_to", "object": "CHEBI:27899", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6376191"], "tmkp_confidence_score": 0.6529963641100585, "sentences": "As shown in Figure 9C-D and Figure S18A, C, HT@CDDP induced a remarkable tumor growth delay and, 13 days after treatment, the tumor size (5.70 ? 1.14 mm3) was reduced by 82.78% compared with the untreated control (33.11 ? 4.63 mm3).|NA", "tmkp_ids": ["tmkp:13577809435a7de92b00b14fc5a14ff8c010a136e900860b78ae02928a9088ea"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001510", "original_object": "DRUGBANK:DB00515"}
{"subject": "MONDO:0002771", "predicate": "biolink:contributes_to", "object": "UMLS:C0005740", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9216512", "PMC:9216512", "PMC:9216512"], "tmkp_confidence_score": 0.7726991358851115, "sentences": "siIL11@PPGC NPs mitigate bleomycin-induced pulmonary fibrosis|NA|Inhalation of siIL11@PPGC NPs restores the pulmonary function in the mouse model of bleomycin-induced pulmonary fibrosis.|NA|Inhaled siIL11@PPGC NPs inhibit fibroblast activation and ECM production in the mouse model of bleomycin-induced pulmonary fibrosis.|NA", "tmkp_ids": ["tmkp:b8912185ebff2fc55c48ddd3bb91b32312272f256b3ba3087342582974ebfea4", "tmkp:78d960c43593a81792c361d16f360bdb8fc50a085c3297351f7e2d72675045ed", "tmkp:853d0a215b0f9905a36e383fdb2b8005b51c7230fe3741bc0b47a75e5d27c143"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0002771", "original_object": "DRUGBANK:DB00290"}
{"subject": "MONDO:0002974", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UMLS:C4086994", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8905681"], "tmkp_confidence_score": 0.9410423252942841, "sentences": "Two clinical studies, INTR@PID 001 (NCT02517398) and NCI 012 (NCT03427411), have evaluated bintrafusp alfa in cohorts of patients with pretreated recurrent or metastatic cervical cancer.|NA", "tmkp_ids": ["tmkp:3e76cf3809937d70e277d222a3094b8c20b3c01afb4653ae6a90285e9c18dc83"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0002974", "original_object": "DRUGBANK:DB15387"}
{"subject": "DRUGBANK:DB11003", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0000969", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9041331"], "tmkp_confidence_score": 0.7674370945190884, "sentences": "An interim analysis of the trial reported data for the first 1005 participants through study Month 7. Participants who received AVA by the IM route experienced a significant (p < 0.05) reduction in occurrence of moderate and severe injection-site AEs (warmth, tenderness, itching, erythema, induration, edema, and nodules) compared with participants who received the vaccine SC, as assessed at in-clinic visits (10.2% SC vs. 7.0% IM; p = 0.04).|NA", "tmkp_ids": ["tmkp:7963652049d062f3690f56579113641b3904d569ef87e96b1f5e8ff3dce8fb3e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB11003", "original_object": "HP:0000969"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:28748", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7828119", "PMC:9323998"], "tmkp_confidence_score": 0.6517418423327936, "sentences": "A photothermal material using Au@m-SiO2 nanocube-loaded doxorubicin (DOX) as the chemotherapeutic drug grafted with Mn-CDs shows multiple applications for hyperthermia, chemotherapy, and oxygen-evolving in situ PDT under bi-irradiation at 635 and 808 nm.|NA|Similarly, Yu et al. developed a H2O2/NIR-responsive nanoplatform (MnPB @polypyrrole [MnPB@PPy]) to load Doxorubicin (DOX) by making MnPB@PPy core?shell-structured nanocarrier for MRI-guided co-chemotherapy/hyperthermia.|NA|A photothermal material using Au@m-SiO2 nanocube-loaded doxorubicin (DOX) as the chemotherapeutic drug grafted with Mn-CDs shows multiple applications for hyperthermia, chemotherapy, and oxygen-evolving in situ PDT under bi-irradiation at 635 and 808 nm.|NA", "tmkp_ids": ["tmkp:00c9801aa27520267ef537ff697b49efd4fb3bbd481bfe2accd1ea3a006268c3", "tmkp:152dc18585b4858139a8c8ffe127bdb7ef97682589f90be966c5934fb6cb0e2f", "tmkp:5565eec35abae850ebfea2e541d06ed82ff04e1a8f63047de8d8de5a22691b89", "tmkp:975c307e877504610e7b1bd232333627c22b8ec0eb39c573408fbb3a2ba9f8e0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00997"}
{"subject": "MONDO:0005292", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UNII:O03S90U1F2", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8965165", "PMC:8965165", "PMC:8965165"], "tmkp_confidence_score": 0.7781131668904292, "sentences": "LUT@TPGS-PBTE NPs rescued the hemoglobin of mice with colitis and showed no significant difference from the normal group.|NA|LUT@TPGS-PBTE NPs regulate CD4+ T lymphocyte subsets balance in colitis mice|NA|Besides, LUT@TPGS-PBTE NPs most effectively inhibited the percentage of Th17??cells (Fig.?7G?I) and suppress the levels of IL-17A protein and mRNA secreted by Th17 in the colitis mice.|NA", "tmkp_ids": ["tmkp:197bf2fb173cb264a2e292cd9338c7fa0f0892c5edf12c56a5c8ae77ec2a9ce8", "tmkp:bad4a4b273d30d8148caaeb143e5ec1a1fc927bd50e88480fcefc5c245359077", "tmkp:a7d4067d611fb4dde702b44581db88527ff5d0ff254161dbafd7ba91548fedb7"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0005292", "original_object": "DRUGBANK:DB11635"}
{"subject": "UniProtKB:P46013", "predicate": "biolink:affects", "object": "CHEBI:31696", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9120472"], "tmkp_confidence_score": 0.999647, "sentences": "Meanwhile, Cal@MPs and Cal/ICG@MPs significantly inhibited the ratios of Ki67-positive proliferative CAFs (Supplementary Fig.?18d).|NA", "tmkp_ids": ["tmkp:1943c62488c59c7ca7592d59b13e048df2778f774f8031845706843541be5cf6"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:P46013", "original_object": "DRUGBANK:DB16024"}
{"subject": "MONDO:0007256", "predicate": "biolink:contributes_to", "object": "CHEBI:50845", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8964448"], "tmkp_confidence_score": 0.6378220604284649, "sentences": "The tissue distribution and chemo- and photodynamic therapeutic effects of HCPT@NMOFs-RGD were evaluated in a doxycycline-induced zebrafish HCC model and xenograft mouse model.|NA", "tmkp_ids": ["tmkp:0551db48f45be7647d28a8fd97e9682c415dad43d1b5a84ad8d8eb3f03af3596", "tmkp:901093f33ce3fcd2f971b24332b789e882a573014b51adc9545625b02ca0b2a3"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0007256", "original_object": "DRUGBANK:DB00254"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UniProtKB:P02768", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7755349"], "tmkp_confidence_score": 0.6184915950211146, "sentences": "Treatment using SPIO@PSS/CDDP/HSA?MTX NPs and RF irradiation allows the CDDP-based chemotherapeutic drug to act synergistically with hyperthermia to provide a profound anticancer effect.|NA", "tmkp_ids": ["tmkp:b2acb3d5f7152b54b1f9fd2acb37195233305b3ec8bc7ec46beef89fa0680ca0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00062"}
{"subject": "HP:0100282", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UNII:O03S90U1F2", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8965165"], "tmkp_confidence_score": 0.99895835, "sentences": "Antioxidant and anti-inflammatory effects of DiR@TPGS-PBTE NPs on acute colitis in mice.|NA", "tmkp_ids": ["tmkp:32c2246be18b5900bef01d1a60d5993e8806621a8217cbbeafe2868e7d40be20"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0100282", "original_object": "DRUGBANK:DB11635"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:27899", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7755349"], "tmkp_confidence_score": 0.6301948966549933, "sentences": "Treatment using SPIO@PSS/CDDP/HSA?MTX NPs and RF irradiation allows the CDDP-based chemotherapeutic drug to act synergistically with hyperthermia to provide a profound anticancer effect.|NA", "tmkp_ids": ["tmkp:daea0d0e44215775373cf3ac352d2aef251ca9686192803c8367f37d0aaaa7d9"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00515"}